Lori Macomber

CIK: 0001968671

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KPTI

Karyopharm Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

KPTI
Karyopharm Therapeutics Inc.
Feb 3, 2026
Sale(S)
Direct
1.6K shares at avg. $6.30$10K
KPTI
Karyopharm Therapeutics Inc.
Jan 31, 2026
Award(A)
Direct
32.4K shares-
KPTI
Karyopharm Therapeutics Inc.
Oct 15, 2025
Award(A)
Direct
43.7K shares-
KPTI
Karyopharm Therapeutics Inc.
Jan 31, 2025
Award(A)
Direct
160K shares-

		Type	Shares	Price		Ownership
Feb 3, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	1,626	$6.30	$10,244	Direct
Jan 31, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	32,415	-	$0	Direct
Oct 15, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	43,650	-	-	Direct
Jan 31, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	160,000	-	-	Direct

1-4 of 4 transactions

About Macomber Lori

Macomber Lori (SEC CIK 0001968671) files insider reports with the SEC as EVP, CFO & Treasurer of Karyopharm Therapeutics Inc. (KPTI).

Signal8 holds 5 ownership filings by Macomber Lori (1 Form 3, 4 Form 4), filed between Jan 6, 2025 and Feb 4, 2026. Those filings report 4 transactions, from Jan 31, 2025 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Macomber Lori's filings is in NEWTON, MA.

Recent filings by Macomber Lori

Feb 3, 2026: Open-market sale of KPTI shares (Form 4, code S).
Jan 31, 2026: Grant or award of KPTI shares (Form 4, code A).
Oct 15, 2025: Grant or award of KPTI shares (Form 4, code A).
Jan 31, 2025: Grant or award of KPTI shares (Form 4, code A).

Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)

Abate Kristin, Chief Accounting Officer
Poulton Stuart, EVP, Chief Development Officer
Oliger Christy J., Director
PAKIANATHAN DEEPIKA, Director
Schor Chen, Director
Su Zhen, Director

How to read Form 4 transaction codes